Published in Br J Cancer on November 01, 1999
Novel imaging provides new insights into mechanisms of oxygen transport in tumors. Curr Mol Med (2009) 0.95
Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium. Transl Oncol (2012) 0.83
Opposing influence of intracellular and membrane thiols on the toxicity of reducible polycations. Biomaterials (2013) 0.81
Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling. Front Oncol (2013) 0.75
Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res (1996) 6.62
Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res (1996) 4.98
Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (1997) 4.55
Glutathione-associated enzymes in anticancer drug resistance. Cancer Res (1994) 3.19
Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol Ther (1991) 2.48
Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol (1998) 2.36
Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res (1993) 1.97
Role of glutathione in the radiation response of mammalian cells in vitro and in vivo. Pharmacol Ther (1990) 1.13
The role of glutathione in radiation and drug induced cytotoxicity. Br J Cancer Suppl (1987) 1.12
Histochemical localization of glutathione in tissues. J Histochem Cytochem (1975) 0.99
Effects of hypoxia on detoxicating enzyme activity and expression in HT29 colon adenocarcinoma cells. Cancer Res (1994) 0.94
Intracellular redox changes during apoptosis. Cell Death Differ (1996) 0.91
Chemical modifiers of cancer treatment. J Clin Oncol (1988) 0.89
Cellular and regional distribution of reduced glutathione in the nervous system of the rat: histochemical localization by mercury orange and o-phthaldialdehyde-induced histofluorescence. Toxicol Appl Pharmacol (1991) 0.85
Glutathione content of V79 cells in two- or three-dimensional culture. Am J Physiol (1997) 0.84
Differential effects of depleting agents on cytoplasmic and nuclear non-protein sulphydryls: a fluorescence image cytometry study. Br J Cancer (1995) 0.84
Radioprotection of DNA in isolated nuclei by naturally occurring thiols at intermediate oxygen tension. Radiat Res (1992) 0.84
Evidence for a hypoxic fixation reaction leading to the induction of ssb and dsb in irradiated DNA. Int J Radiat Biol (1998) 0.83
A cytochemical stain for glutathione in rat hepatocytes cultured on plastic. J Histochem Cytochem (1987) 0.81
Cysteine concentrations in rodent tumors: unexpectedly high values may cause therapy resistance. Int J Cancer (1996) 0.79
Glutathione manipulation and the radiosensitivity of human tumour and fibroblast cell lines. Int J Radiat Biol (1995) 0.79
Cellular glutathione content and K values. II. Int J Radiat Biol (1989) 0.78
Role of glutathione in the aerobic radiation response. Int J Radiat Oncol Biol Phys (1989) 0.78
Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem (1983) 9.40
Clinical and biological significance of aneuploidy in human tumours. J Clin Pathol (1984) 2.39
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer (2006) 2.23
Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry (1985) 1.78
Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry (1993) 1.77
Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res (2000) 1.69
Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res (1984) 1.58
Association of involvement in psychological self-regulation with longer survival in patients with metastatic cancer: an exploratory study. Adv Mind Body Med (2000) 1.48
Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer (2009) 1.47
Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res (2001) 1.47
Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan. Lancet (1978) 1.40
Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res (1987) 1.40
Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry (2001) 1.36
Monocytes and macrophages in malignant melanoma. I. Peripheral blood macrophage precursors. Br J Cancer (1977) 1.30
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer (2008) 1.27
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer (2006) 1.24
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood (1999) 1.24
Immunohistochemical detection of proliferating cells in vivo. J Histochem Cytochem (1987) 1.22
Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res (2000) 1.20
Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides. Br J Cancer (2004) 1.17
Simultaneous detection of mitochondrial respiratory chain activity and reactive oxygen in digitonin-permeabilized cells using flow cytometry. Cytometry (2000) 1.14
High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol (1979) 1.13
Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res (2001) 1.12
Influence of cellular DNA content on disease-free survival of Stage II breast cancer patients. Cancer Res (1984) 1.11
Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. Br J Cancer (1983) 1.11
Flow cytometric analysis of cellular DNA content as an adjunct to the diagnosis of ovarian tumours of borderline malignancy. Pathology (1984) 1.11
The influence of age on the DNA ploidy levels of breast tumours. Eur J Cancer Clin Oncol (1983) 1.09
Contamination of mononuclear cell suspensions obtained from cancer patients by the Böyum method. Br J Cancer (1978) 1.08
Metastatic adeno or undifferentiated carcinoma from an unknown primary site--natural history and guidelines for identification of treatable subsets. Q J Med (1987) 1.08
The prognostic significance of proliferative activity in poor histology non-Hodgkin's lymphoma: a flow cytometry study using archival material. Eur J Cancer Clin Oncol (1987) 0.99
Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol (1988) 0.97
Measurement of intracellular pH. Methods Cell Biol (1990) 0.96
Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. Clin Cancer Res (1997) 0.95
Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer. Br J Cancer (1985) 0.95
Monocytes and macrophages in malignant melanoma. III. Reduction of nitroblue tetrazolium by peripheral blood monocytes. Br J Cancer (1978) 0.94
Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood (2001) 0.94
Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma (2000) 0.90
Relationships between the mitochondrial permeability transition and oxidative stress during ara-C toxicity. Cancer Res (1997) 0.89
Evaluation of baclofen (Lioresal) for spasticity in multiple sclerosis. Postgrad Med J (1975) 0.89
Bcl-2 targeted to the endoplasmic reticulum can inhibit apoptosis induced by Myc but not etoposide in Rat-1 fibroblasts. Oncogene (1999) 0.89
Measurement of cellular DNA content as an adjunct to diagnostic cytology in malignant effusions. Eur J Cancer Clin Oncol (1984) 0.88
Constitutive expression of P-glycoprotein as a determinant of loading with fluorescent calcium probes. Cytometry (1994) 0.88
Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res (1995) 0.87
Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res (1995) 0.87
Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy. Eur J Cancer (1977) 0.87
A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response. Leukemia (2011) 0.86
ICI D1694 and idoxuridine: a synergistic antitumor combination. Cancer Res (1994) 0.85
Differential effects of depleting agents on cytoplasmic and nuclear non-protein sulphydryls: a fluorescence image cytometry study. Br J Cancer (1995) 0.84
p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leuk Res (1999) 0.84
An oxidative stress-mediated death pathway in irradiated human leukemia cells mapped using multilaser flow cytometry. Radiat Res (1998) 0.84
Respiratory chain-generated oxidative stress following treatment of leukemic blasts with DNA-damaging agents. Exp Cell Res (2001) 0.84
Microregional heterogeneity of non-protein thiols in cervical carcinomas assessed by combined use of HPLC and fluorescence image analysis. Clin Cancer Res (2000) 0.83
Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study. Cytometry A (2003) 0.82
Inhibition of gamma-glutamyl transpeptidase activity decreases intracellular cysteine levels in cervical carcinoma. Cancer Chemother Pharmacol (2004) 0.82
Transferrin receptor cycling by human lymphoid cells: lack of effect from inhibition of microtubule assembly. Biochem Biophys Res Commun (1986) 0.82
Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis. Br J Cancer (1995) 0.82
Measurement of intracellular pH. Methods Cell Biol (1994) 0.82
Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence. Br J Cancer (1978) 0.81
Monocytes and macrophages in malignant melanoma IV. Effects of C. parvum on monocyte function. Br J Cancer (1979) 0.81
Regulation of intracellular pH in subpopulations of cells derived from spheroids and solid tumours. Br J Cancer (1993) 0.80
The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2. Cell Death Differ (2001) 0.80
Metastatic adenocarcinoma of unknown primary site: abnormalities of cellular DNA content and survival. Eur J Cancer Clin Oncol (1985) 0.80
Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. Br J Cancer (1979) 0.80
Cell cycle effects of iron depletion on T-47D human breast cancer cells. Exp Cell Res (1985) 0.79
Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topoisomerase II. Biochem Cell Biol (1992) 0.78
Differential effects of buthionine sulphoximine in hypoxic and non-hypoxic regions of human cervical carcinoma xenografts. Radiother Oncol (2001) 0.78
BAD induces apoptosis in cells over-expressing Bcl-2 or Bcl-xL without loss of mitochondrial membrane potential. Leuk Lymphoma (2001) 0.77
Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia. Leukemia (1995) 0.77
DNA flow cytometry of paraffin-embedded tissue. Cytometry (1984) 0.77
Effects of topoisomerase I inhibition on the expression of topoisomerase II alpha measured with fluorescence image cytometry. Cytometry (1996) 0.76
Protection from radiation-induced DNA single-strand breaks by induction of nuclear metallothionein. Int J Radiat Biol (2000) 0.76
DNA flow cytometric study of 5-fluorouracil used to treat end stage non-Hodgkin's lymphoma. Br J Cancer (1987) 0.75
The Queensland Melanoma Project. Br Med J (1979) 0.75
A comparison of combination chemotherapy using vindesine or vincristine with adriamycin in the treatment of advanced breast carcinoma. Cancer Treat Rev (1980) 0.75
Macrophage precursors in ovarian carcinoma. Gynecol Oncol (1979) 0.75
Biochemical modulation of iododeoxyuridine by N6-[4-(morpholinosulfonyl)benzyl]-N6-methyl-2,6-diaminobenz[cd]indole glucuronate (AG-331) leading to enhanced cytotoxicity. Biochem Pharmacol (1995) 0.75
Vindesine: a phase II study in the treatment of breast carcinoma, malignant melanoma, and other tumors. Cancer Treat Rep (1978) 0.75
Mitolactol chemotherapy for malignant melanoma: a phase II study. Cancer Treat Rep (1984) 0.75
Letter: Bioavailability of drugs after intramuscular injection. Lancet (1975) 0.75
Gemcitabine-induced acute myositis in a patient with duodenal cancer. Clin Oncol (R Coll Radiol) (2011) 0.75
Fine-needle aspiration of bone marrow from sternum. Lancet (1982) 0.75
Imaging of whole tumor cut sections using a novel scanning beam confocal fluorescence MACROscope. J Biomed Opt (2001) 0.75
Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer. Cancer Chemother Pharmacol (1985) 0.75
Feasibility of obtaining breast epithelial cells from healthy women for studies of cellular proliferation. Breast Cancer Res Treat (1997) 0.75